News
-
An article in the May 5 issue of the New England Journal of Medicine finds leukotriene-receptor antagonists (LTRAs) such as montelukast (Singulair) as effective as ICS as a first-line treatment for asthma and as effective… Read more . . .
-
On the final day of RDD Europe 2011 in Berlin, most of the focus turned to the abbreviated impactor method (AIM) and efficient data analysis (EDA), but the first session of the morning was devoted… Read more . . .
-
Rigel Pharmaceuticals says it will assume development responsibilities for R343, an inhaled syk inhibitor for the treatment of allergic asthma after Pfizer returned all rights to the program. Pfizer had licensed R343, along with other… Read more . . .
-
The most intense discussions of Day 2 of RDD Europe occurred during an afternoon session on LABA and LABA/ICS postmarket trial design in which industry representatives differed with each other and with regulators over the… Read more . . .
-
According to reports, GlaxoSmithKline has invested an additional $6.7 million in Theravance, its partner in developing a number of inhaled asthma and COPD drugs. The purchase of common stock gives GSK approximately 19% of Theravance’s… Read more . . .
-
Steroid manufacturers Sterling S.r.l., located in Perugia, Italy, is now producing APIs for respiratory delivery using particle engineering technology supplied by Prosonix. A two-year collaboration between the two companies has resulted in a retrofit of… Read more . . .
-
At the kickoff of RDD Europe 2011 in Berlin, Peter Byron of co-organizer RDD provided some attendance figures to the assembled delegates, telling the crowd that they number 470 in all, with ~85% of attendees… Read more . . .
-
MicroDose Therapeutx has announced that it has achieved a milestone that “signals the successful incorporation of MicroDose’s DPI technology into a Novartis platform pulmonary device” and triggers a milestone payment from Novartis. The two companies… Read more . . .
-
A Phase 2 clinical trial of its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis has demonstrated significantly significant improvement in total nasal symptoms compared to placebo, announced ISTA Pharmaceuticals. The study… Read more . . .
-
The US FDA has issued a letter informing stakeholders that it will not appeal a December 2010 ruling by the US Court of Appeals for the DC Circuit that the agency has no authority to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden